Recent Finacing
Recent Raise
Tachyon Therapeutics develops oncology small molecules targeting KDM4 demethylases, holds exclusive KDM4 license, advanced TACH101 to Phase 1 for solid tumors, and operates a core team with virtual network.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
